CC BY-NC-ND 4.0 · Endosc Int Open 2020; 08(02): E147-E154
DOI: 10.1055/a-1038-4012
Original article
Owner and Copyright © Georg Thieme Verlag KG 2020

Antireflux mucosectomy band in treatment of refractory gastroesophageal reflux disease: a pilot study for safety, feasibility and symptom control

Laurent Monino
1   Department of Hepatogastroenterology, Université catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium
2   Department of Hepatogastroenterology, Assistance Publique des Hôpitaux de Marseille, Aix-Marseille Université, Hôpital Nord, Marseille, France
,
Jean-Michel Gonzalez
2   Department of Hepatogastroenterology, Assistance Publique des Hôpitaux de Marseille, Aix-Marseille Université, Hôpital Nord, Marseille, France
,
Véronique Vitton
2   Department of Hepatogastroenterology, Assistance Publique des Hôpitaux de Marseille, Aix-Marseille Université, Hôpital Nord, Marseille, France
,
Marc Barthet
2   Department of Hepatogastroenterology, Assistance Publique des Hôpitaux de Marseille, Aix-Marseille Université, Hôpital Nord, Marseille, France
› Author Affiliations
Further Information

Publication History

submitted 15 July 2019

accepted after revision 09 October 2019

Publication Date:
22 January 2020 (online)

Abstract

Background and study aims Antireflux mucosectomy band ligation (ARM-b) is an endoscopic procedure that mimics a fundoplication for managing gastroesophoageal reflux disease (GERD). The aim of this study was to assess safety and feasibility of ARM-b.

Patients and methods This was a single-center study on consecutive patients operated between June 2017 and January 2019 with refractory GERD, confirmed with pH-metry and without motility disorder at high-resolution manometry. A piecemeal mucosectomy of three quarters of circumference of esophagogastric junction was performed using a band ligation system and a hexagonal snare. The primary objective was to assess procedural safety and feasibility. The secondary objective was to document the clinical improvement at 3 and 6 months based on patient satisfaction, proton pump inhibitor (PPI) intake, symptoms, and quality of life scores.

Results Twenty-onepatients (11 men) with mean age 56.9 ± 14.4 years were analyzed. The technical success rate was 100 % (mean duration 35 ± 11 min). Four patients (19 %) had mild adverse events: one delayed bleeding at Day 1 managed conservatively, and three dysphagia endoscopically managed. Mean follow-up was 10 ± 5 months. Decrease/discontinuation of PPI intake was 76 % at 3 months and 72 % at 6 months. Improvement in mean symptoms and quality of life scores (GERD-Q and GERD-HQL) were statistically significant. One patient required laparoscopic fundoplication after ARM-b failure without complication.

Conclusion ARM-b is safe, feasible, and symptom-effective for treating refractory GERD, and it can be performed in the ambulatory setting. Further prospective studies are required to confirm these promising outcomes.

 
  • References

  • 1 Savarino E, Marabotto E, Bodini G. et al. Epidemiology and natural history of gastroesophageal reflux disease. Minerva Gastroenterol Dietol 2017; 63: 175-183
  • 2 Gyawali CP, Fass R. Management of gastroesophageal reflux disease. Gastroenterology 2018; 154: 302-318
  • 3 Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013; 108: 308-328
  • 4 Labenz J, Malfertheiner P. Treatment of uncomplicated reflux disease. World J Gastroenterol 2005; 11: 4291
  • 5 Yang X-J, Jiang H-M, Hou X-H. et al. Anxiety and depression in patients with gastroesophageal reflux disease and their effect on quality of life. World J Gastroenterol 2015; 21: 4302
  • 6 Lee S-W, Lien H-C, Lee T-Y. et al. Heartburn and regurgitation have different impacts on life quality of patients with gastroesophageal reflux disease. World J Gastroenterol 2014; 20: 12277
  • 7 Mizuki A, Tatemichi M, Sakakibara T. et al. A multicenter, randomized, open-label trial: efficacy of once-daily versus twice-daily double-dose rabeprazole on refractory gastroesophageal reflux disease-related symptoms and quality of life. Curr Ther Res Clin Exp 2016; 79: 1
  • 8 Vakil N, van Zanten SV, Kahrilas P. et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-1920
  • 9 Lundell L, Miettinen P, Myrvold HE. et al. Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clin Gastroenterol Hepatol 2009; 7: 1292-1298
  • 10 Davis CS, Baldea A, Johns JR. et al. The evolution and long-term results of laparoscopic antireflux surgery for the treatment of gastroesophageal reflux disease. JSLS J Soc Laparoendosc Surg 2010; 14: 332-341
  • 11 Ganz RA. A review of new surgical and endoscopic therapies for gastroesophageal reflux disease. Gastroenterol Hepatol (NY) 2016; 12: 424-31
  • 12 Pearl J, Pauli E, Dunkin B. et al. SAGES endoluminal treatments for GERD. Surg Endosc 2017; 31: 3783-3790
  • 13 Thosani N, Goodman A, Manfredi M. et al. Endoscopic anti-reflux devices (with videos). Gastrointest Endosc 2017; 86: 931-948
  • 14 Inoue H, Ito H, Ikeda H. et al. Anti-reflux mucosectomy for gastroesophageal reflux disease in the absence of hiatus hernia: a pilot study. Ann Gastroenterol 2014; 27: 346-351
  • 15 Monino L, Gonzalez J-M, Vitton V. et al. Anti-reflux mucosectomy with band ligation in the treatment of refractory gastroesophageal reflux disease. Endoscopy 2019; 51: E215-E216
  • 16 Kahrilas PJ, Bredenoord AJ, Fox M. et al. The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil 2015; 27: 160-174
  • 17 Kahrilas PJ, Sifrim D. High-resolution manometry and impedance-pH/manometry: valuable tools in clinical and investigational esophagology. Gastroenterology 2008; 135: 756-769
  • 18 Savarino E, Tutuian R, Zentilin P. et al. Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH off therapy. Am J Gastroenterol 2010; 105: 1053-1061
  • 19 Picon L, Bruley Des Varannes S. Groupe de Travail sur les Recommandations pour lapratique de la pHmétrie esophagienne. Guidelines for esophageal pH-monitoring in adults. Gastroenterol Clin Biol 2000; 24: 931-943
  • 20 Roman S, Gyawali CP, Savarino E. et al. Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: Update of the Porto consensus and recommendations from an international consensus group. Neurogastroenterol Motil 2017; 29: e13067
  • 21 Gyawali CP, Kahrilas PJ, Savarino E. et al. Modern diagnosis of GERD: the Lyon Consensus. Gut 2018; 67: 1351-1362
  • 22 Jones R, Junghard O, Dent J. et al. Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther 2009; 30: 1030-1038
  • 23 Velanovich V. The development of the GERD-HRQL symptom severity instrument. Dis Esophagus 2007; 20: 130-134
  • 24 Chassany O, Holtmann G, Malagelada J. et al. Systematic review: health-related quality of life (HRQOL) questionnaires in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008; 27: 1053-1070
  • 25 Gandek B, Ware JE, Aaronson NK. et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998; 51: 1171-1178
  • 26 Brazier JE, Harper R, Jones NM. et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992; 305: 160-164
  • 27 Cotton PB, Eisen GM, Aabakken L. et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc 2010; 71: 446-454
  • 28 Wendling MR, Melvin WS, Perry KA. Impact of transoral incisionless fundoplication (TIF) on subjective and objective GERD indices: a systematic review of the published literature. Surg Endosc 2013; 27: 3754-3761
  • 29 Lipka S, Kumar A, Richter JE. No evidence for efficacy of radiofrequency ablation for treatment of gastroesophageal reflux disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2015; 13: 1058-1067.e1
  • 30 Zacherl J, Roy-Shapira A, Bonavina L. et al. Endoscopic anterior fundoplication with the Medigus Ultrasonic Surgical Endostapler (MUSETM) for gastroesophageal reflux disease: 6-month results from a multi-center prospective trial. Surg Endosc 2015; 29: 220-229
  • 31 Pouw RE, Beyna T, Belghazi K. et al. A prospective multicenter study using a new multiband mucosectomy device for endoscopic resection of early neoplasia in Barrett’s esophagus. Gastrointest Endosc 2018; 88: 647-654
  • 32 Becher A, El-Serag H. Systematic review: the association between symptomatic response to proton pump inhibitors and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2011; 34: 618-627
  • 33 Wileman SM, McCann S, Grant AM. et al. Medical versus surgical management for gastro-oesophageal reflux disease (GORD) in adults. In: Wileman SM. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; CD003243
  • 34 Krill JT, Naik RD, Higginbotham T. et al. Association between response to acid-suppression therapy and efficacy of antireflux surgery in patients with extraesophageal reflux. Clin Gastroenterol Hepatol 2017; 15: 675-681
  • 35 Oelschlager BK, Quiroga E, Parra JD. et al. Long-term outcomes after laparoscopic antireflux surgery. Am J Gastroenterol 2008; 103: 280-287; quiz 288